Craft
  • Home
  •  / Reata Pharmaceuticals
Reata Pharmaceuticals

Reata Pharmaceuticals

Patents Issued

240

FY, 2016

Revenue

$11.5 M

FY, 2021

Market Capitalization

$1.4 B

2022-11-18

Reata Pharmaceuticals Summary

Company summary

Overview
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Type
Public
Status
Active
Founded
2002
HQ
Plano, TX, US | view all locations
Website
http://reatapharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Warren Huff

    Warren Huff, Founding Chief Executive Officer and President, Director

  • Colin Meyer

    Colin Meyer, Chief Innovation Officer and Executive Vice President

  • Dawn C. Bir

    Dawn C. Bir, Chief Commercial Officer and Executive Vice President

  • Manmeet S. Soni

    Manmeet S. Soni, President, Chief Operating Officer and Chief Financial Officer

Operating MetricsView all

Patents Issued

240

FY, 2016

Phase III Trials Products

1

FY, 2016

Phase II Trials Products

4

FY, 2016

LocationsView all

3 locations detected

  • Plano, TX HQ

    United States

    5320 Legacy Dr

  • Irving, TX

    United States

    2801 Gateway Dr #150

  • Plano, TX

    United States

    5340 Legacy Dr

Reata Pharmaceuticals Financials

Summary financials

Revenue (Q3, 2022)
$540.0K
Net income (Q3, 2022)
($79.0M)

Footer menu